Abiopharma

Dividend in the amount of $0.19 per share, ex-date: 2.9.26, payment 10.9.26

Management and officers – staffing as of 12.8.26

The company’s outstanding liabilities as of June 30, 2026, by maturity dates

The company’s outstanding obligations as of 30.6.26, by maturity dates

Q2/half-year report for 2026

Q2/half-year report for 2026

Financing agreement in the amount of approximately 229 million euros for the Parau 2 project in Romania

Initiation of negotiations and due diligence for investment in a company in the United States

Dormant shares – creation of dormant shares

CMB.TECH ANNOUNCES Q2 2026 RESULTS ON 27/08/2026